Every Form 4 that Heartbeam, Inc. Warrant (BEATW) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BEATW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BEATW filings page.
HeartBeam, Inc. reported that Chief Technology Officer Kenneth Harry Persen acquired 105,740 shares of common stock on July 24, 2026 through a grant treated as Restricted Stock Units under the 2022 Equity Incentive Plan.
The RSUs vested in full on the grant date as part of the 2025 Bonus Program, with executives receiving shares in lieu of cash. Following this award, Persen directly holds 448,290 shares of HeartBeam common stock.
Cruickshank Tim reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. reported that CFO Tim Cruickshank received a grant of 167,760 shares of common stock in the form of Restricted Stock Units on July 24, 2026 under the 2022 Equity Incentive Plan. The RSUs vested in full on the grant date as shares-in-lieu-of-cash for the 2025 Bonus Program, increasing his directly held shares to 239,990.
Vajdic Branislav reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. reported equity awards to President and director Branislav Vajdic under its 2022 Equity Incentive Plan. On June 15, 2026 he was granted 2,800,000 performance-based PRSUs that vest over three years upon achievement of milestones and continued service. On July 24, 2026 he received 260,870 RSUs, which vested in full on the grant date and settled his 2025 bonus in shares instead of cash.
HeartBeam, Inc. director Richard Ferrari increased his stake by purchasing 57,500 shares of common stock at $0.80 per share. The buy was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners acted as sole bookrunner.
This amended Form 4 corrects Ferrari’s previously reported acquisition and total beneficial ownership. The original filing mistakenly showed 62,500 shares acquired; the correct figure is 57,500 shares. Following this transaction, Ferrari beneficially owns 286,636 shares of HeartBeam common stock directly.
HeartBeam, Inc. CFO Tim Cruickshank increased his stake by buying 31,250 shares of common stock at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock.
The offering priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners, a division of American Capital Partners, acting as sole bookrunner. After this transaction, Cruickshank directly owns 72,230 shares, including 23,333 RSUs that have vested.
HeartBeam, Inc. director Willem Elfrink reported an open-market purchase of common stock. On April 16, 2026, he bought 187,500 shares at $0.80 per share, bringing his direct holdings to 538,667 shares.
According to the footnote, these shares were purchased in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026, with Titan Partners acting as sole bookrunner.
HeartBeam, Inc. director-associated entity Open Book Healthcare purchased 31,250 shares of common stock in an open-market transaction on April 16, 2026, at $0.80 per share. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 shares of common stock, which priced on April 14, 2026 and closed on April 16, 2026. Following this transaction, 31,250 shares are held indirectly for the benefit of Michael R. Jaff through Open Book Healthcare.
HeartBeam, Inc. director Branislav Vajdic made an open-market purchase of 31,250 shares of common stock at $0.80 per share. After this transaction, he directly owns 909,914 shares.
The shares were bought in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, for which Titan Partners, a division of American Capital Partners, acted as sole bookrunner. The offering priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Richard Ferrari reported an open-market purchase of 62,500 shares of common stock at $0.80 per share. Following this buy, he directly holds 291,636 shares. The purchase was made in connection with HeartBeam’s underwritten public offering of 12,500,000 common shares, which priced on April 14, 2026 and closed on April 16, 2026.
HeartBeam, Inc. director Marga Ortigas-Wedekind received a grant of stock options representing the right to buy 44,827 shares of common stock at an exercise price of $1.43 per share. This is a compensation-related award, not an open-market share purchase or sale.
According to the grant terms, one half of the options, covering 22,413.5 underlying shares, will vest on March 31, 2026, and the remaining half will vest on June 30, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and expire on January 1, 2036, giving the director a long-term incentive tied to the company’s share performance.
HeartBeam, Inc. reported that major shareholder Mark E. Strome received a grant of stock options to acquire 41,380 shares of common stock at an exercise price of $1.43 per share. Half of these options vest on March 31, 2026 and the remaining half on June 30, 2026, with an expiration date of January 1, 2036. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent compensation rather than an open-market purchase or sale.
HeartBeam, Inc. director receives equity award. Director Michael R. Jaff acquired 20,689 shares of HeartBeam common stock as a grant of restricted stock units (RSUs) at no cash cost on February 9, 2026. Following this award, he holds 95,809 shares directly.
The RSUs were granted under the company’s 2022 Equity Incentive Plan. One half of the shares subject to this special RSU grant are scheduled to vest on March 31, 2026, with the remaining half scheduled to vest on June 30, 2026, subject to the stated vesting terms.
HeartBeam, Inc. reported that President and director Branislav Vajdic received a grant of options to buy 61,932 shares of common stock at an exercise price of $1.45 per share. The options were granted on February 9, 2026 and expire on January 1, 2036.
According to the vesting terms, one half of the shares subject to this special option will vest on March 31, 2026, with the remaining shares vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. After this grant, Vajdic holds options for 61,932 underlying shares under the company’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported a routine equity compensation grant to its CFO, Tim Cruickshank. He received stock options covering 53,104 shares of common stock at an exercise price of $1.45 per share. Half of these options vest on March 31, 2026 and the remainder on June 30, 2026 under the 2022 Equity Incentive Plan.
HeartBeam, Inc. director Willem Elfrink received a stock option grant covering 51,724 shares of common stock on February 9, 2026. The options have an exercise price of $1.43 per share and expire on January 1, 2036.
According to the vesting terms, half of the shares subject to this “Special Option” vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options were issued under HeartBeam’s 2022 Equity Incentive Plan and represent Elfrink’s reported derivative holdings following this award.
Nelson Kenneth Warwick III reported acquisition or exercise transactions in this Form 4 filing.
HeartBeam, Inc. director Nelson Kenneth Warwick III reported a compensation grant of 17,241 restricted stock units (RSUs) of common stock. These RSUs were granted on February 9, 2026 at no cash cost and increase his direct holdings to 144,388 shares.
According to the grant terms, one half of the RSUs will vest on March 31, 2026, and the remaining half will vest on June 30, 2026, based on a vesting commencement date of January 1, 2026. The award was issued under HeartBeam’s 2022 Equity Incentive Plan, highlighting routine equity-based director compensation rather than an open-market purchase.
HeartBeam, Inc. director George de Urioste received a grant of options to acquire 51,724 shares of common stock at an exercise price of $1.43 per share. Following this award, he holds options covering 51,724 shares.
According to the grant terms, one half of the shares subject to this "Special Option" vest on March 31, 2026, with the remaining half vesting on June 30, 2026, based on a vesting commencement date of January 1, 2026. The options expire on January 1, 2036 and were issued under HeartBeam’s 2022 Equity Incentive Plan.
HeartBeam, Inc. reported that President Robert Paul Eno received an option grant covering 55,172 shares of common stock at an exercise price of $1.45 per share. The award, granted on February 9, 2026, vests half on March 31, 2026 and the remainder on June 30, 2026, and expires on January 1, 2036. These options were issued under the company’s 2022 Equity Incentive Plan and represent equity-based compensation rather than an open-market stock purchase.